Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals develops RNA interference medicines for rare and cardiovascular diseases from its base in Cambridge, Massachusetts. It last closed at $156.50 on Nov 17, down 2.02% on the day. ALNY reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 17 analysts is $284.24 (+81.6% from the last close), with a high of $380.00 and a low of $199.00. Analyst consensus is Buy, based on the latest ratings from 17 firms (11 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 12 whale options trades in ALNY, 42% of them bullish and 58% bearish. In the past 30 days there were 13 dark pool prints totaling $40.5M, the largest $9.6M.
Key Stats
Last 12 monthsNot reported for this period.
From ALNY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 17 analysts who set a price target on ALNY in the past 90 days. The average target is $284.24, with a high of $380.00 and a low of $199.00, compared with the last close of $156.50.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | HC Wainwright & Co. | Target lowered | Buy | $455 → $250 |
| Nov 17 | Cantor Fitzgerald | Maintained | Hold | $205 |
| Nov 2 | Barclays | Target lowered | Buy | $450 → $380 |
| Nov 2 | Truist Securities | Downgrade | Hold | $315 → $225 |
| Nov 2 | Canaccord Genuity | Maintained | Buy | $323 |
Technical Analysis
The stock is 15% below its 20 day and 37% below its 50 day average. It is 75% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the swing low (Nov 2) at $156.00, and the nearest resistance the Pivot at $157.64.
| RSI (14) | 31.17 | Weak, oversold below 30 | Neutral |
| MACD | -18.47 | Above its signal line | Bullish |
| Stochastic | 15.1 | Near the bottom of its range | Oversold |
| ADX (14) | 31.8 | Trending down | |
| Williams %R | -86.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -56.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.1% | Change over 10 sessions | Bearish |
| ATR (14) | $9.99 | Typical daily range, 6.4% of price |
| RSI (14) | 30.05 | Weak, oversold below 30 | Neutral |
| MACD | -34.21 | Below its signal line | Bearish |
| Stochastic | 6.8 | Near the bottom of its range | Oversold |
| ADX (14) | 20.6 | Weak trend | |
| Williams %R | -94.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -170.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −37.1% | Change over 10 sessions | Bearish |
| ATR (14) | $26.78 | Typical daily range, 17.1% of price |
What happened before
See how ALNY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ALNY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ALNY in the last 90 days.
Dark Pool
30DALNY Institutional Ownership
Full report →- ●381 buying vs 404 selling
- ▲Held by funds +3.9 pts
- ▼Funds holding -65
- ▼Superinvestors: 1 added, 2 cut
- ▼Put/call 0.56 to 0.64
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 733 | 798 | −8.1% |
| In funds' top 10 | 3 | 6 | −50.0% |
| Held by funds | 104.7% | 100.8% | +3.9 pts |
| New / increased | 88 / 293 | 81 / 324 | −5.9% |
| Reduced / sold out | 257 / 147 | 282 / 87 | +9.5% |
| Put/call ratio | 0.64 | 0.56 | +13.2% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALNY is in one of them and how their past ALNY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALNY in an article yet. Here's the latest on the wider market.
ALNY Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Buy | $1K – $15K | Aug 28, 2026 | Sep 22, 2026 | 25 d |
| Donald J TrumpExecutive branch | Buy | $1K – $15K | Aug 10, 2026 | Sep 22, 2026 | 43 d |
| Donald J TrumpExecutive branch | Buy | $1K – $15K | Jul 17, 2026 | Sep 22, 2026 | 67 d |
| Cory BookerD · NJ | Sell | $1K – $15K | Aug 11, 2026 | Sep 9, 2026 | 29 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | May 18, 2026 | Jul 1, 2026 | 44 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines based on RNA interference, a natural process cells use to switch off specific genes. Its approved treatments address hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, high cholesterol and hemophilia, with some sold through partners. Its customers are patients with rare and cardiovascular diseases, along with the doctors and health systems that treat them.
- Headquarters
- Cambridge, MA
- Founded
- 2002
- Website
- alnylam.com ↗








